MX352974B - Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. - Google Patents
Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.Info
- Publication number
- MX352974B MX352974B MX2013008836A MX2013008836A MX352974B MX 352974 B MX352974 B MX 352974B MX 2013008836 A MX2013008836 A MX 2013008836A MX 2013008836 A MX2013008836 A MX 2013008836A MX 352974 B MX352974 B MX 352974B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- nucleic acid
- vaccine
- same
- acid molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a secuencias de ácidos nucleicos que codifican nuevas secuencias de aminoácidos consenso de antígenos del virus del herpes, así como construcciones/vectores genéticos y vacunas que expresan las secuencias. En la presente también se proporcionan métodos para generar una respuesta inmunitaria contra el virus del herpes utilizando las vacunas que se proporcionan.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161438089P | 2011-01-31 | 2011-01-31 | |
PCT/US2012/023398 WO2012106377A2 (en) | 2011-01-31 | 2012-01-31 | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013008836A MX2013008836A (es) | 2013-12-06 |
MX352974B true MX352974B (es) | 2017-12-15 |
Family
ID=46603275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013008836A MX352974B (es) | 2011-01-31 | 2012-01-31 | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. |
Country Status (12)
Country | Link |
---|---|
US (2) | US9243041B2 (es) |
EP (1) | EP2670443A4 (es) |
JP (3) | JP6099573B2 (es) |
KR (1) | KR20140007404A (es) |
CN (2) | CN103827131B (es) |
AU (2) | AU2012212264B2 (es) |
BR (1) | BR112013020070A8 (es) |
CA (1) | CA2826199A1 (es) |
EA (1) | EA033467B1 (es) |
HK (1) | HK1198538A1 (es) |
MX (1) | MX352974B (es) |
WO (1) | WO2012106377A2 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
DK4066855T3 (da) | 2010-08-31 | 2023-02-20 | Glaxosmithkline Biologicals Sa | Pegylerede liposomer til forsyning af RNA, der koder for immunogen |
TR201903651T4 (tr) | 2010-10-11 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Antijen uygulama platformları. |
US11896636B2 (en) | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
CN104853771A (zh) | 2012-07-06 | 2015-08-19 | 诺华股份有限公司 | 巨细胞病毒蛋白的复合物 |
CA2879577C (en) * | 2012-07-27 | 2021-08-03 | City Of Hope | An mva vaccine for delivery of a ul128 complex and preventing cmv infection |
EP2892913A4 (en) * | 2012-09-07 | 2017-01-18 | Agency For Science, Technology And Research | Peptides and their uses |
AU2013358944B2 (en) | 2012-12-13 | 2016-08-18 | Inovio Pharmaceuticals, Inc. | DNA antibody constructs and method of using same |
WO2014093897A1 (en) * | 2012-12-13 | 2014-06-19 | The Trustees Of The University Of Pennsylvania | Wt1 vaccine |
US9732123B2 (en) * | 2013-03-15 | 2017-08-15 | The Trustees Of The University Of Pennsylvania | Mono or multivalent botulinum neurotoxin based vaccine using the heavy chain from serotypes of Clostridium botulinum |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015165480A1 (en) * | 2014-04-30 | 2015-11-05 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
EP3134117A1 (en) * | 2014-04-23 | 2017-03-01 | Institute for Research in Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
WO2015168650A2 (en) * | 2014-05-02 | 2015-11-05 | University Of Washington | Epitopes cross-reactive between hsv-1, hsv-2 and vzv and methods for using same |
PE20170301A1 (es) * | 2014-05-08 | 2017-03-30 | Pfizer | Medios y metodos para el tratamiento cmv |
WO2016036503A1 (en) * | 2014-09-04 | 2016-03-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Antigen compositions and methods of use for treating extraintestinal pathogenic e. coli infections |
KR101723605B1 (ko) * | 2014-10-21 | 2017-04-07 | 진원생명과학 주식회사 | 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법 |
AU2015355126B9 (en) | 2014-12-01 | 2020-03-26 | Inovio Pharmaceuticals, Inc. | DNA antibody constructs and method of using same |
CN105669838B (zh) * | 2014-12-04 | 2020-10-16 | 厦门大学 | 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体 |
AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
BR112018008090A2 (pt) * | 2015-10-22 | 2018-11-13 | Modernatx Inc | vacina de vírus do herpes simplex. |
CA3002912A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
JP7012365B2 (ja) * | 2016-02-25 | 2022-03-04 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ジカウイルスに対する新規のワクチン |
EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | VACCINE AGAINST THE HUMANE CYTOMEGALOVIRUS |
RU2736472C2 (ru) * | 2016-11-18 | 2020-11-17 | Общество с ограниченной ответственностью "ЭКСИФАРМ" | Химерный белок, синтетическая днк, кодирующая указанный белок, экспрессионный вектор, штамм-продуцент синтетической днк и способ получения плазмидной днк |
US11572389B2 (en) * | 2017-01-27 | 2023-02-07 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccine compositions of herpesvirus envelope protein combinations to induce immune response |
WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
CN108727503A (zh) * | 2017-04-18 | 2018-11-02 | 武汉博沃生物科技有限公司 | VZV重组gE-鞭毛素融合蛋白及其制备方法和应用 |
MA49463A (fr) * | 2017-04-26 | 2021-05-05 | Modernatx Inc | Vaccin contre le virus de l'herpès simplex |
EP3677592B1 (en) * | 2017-08-30 | 2024-07-17 | KM Biologics Co., Ltd. | Modified hsv gd protein and vaccine containing same |
CN108315344A (zh) * | 2018-02-14 | 2018-07-24 | 武汉博沃生物科技有限公司 | Vzv糖蛋白e基因表达载体及其重组酵母菌株与应用 |
WO2019161163A1 (en) * | 2018-02-16 | 2019-08-22 | The Wistar Institute Of Anatomy And Biology | Epstein-barr virus nucleic acid constructs and vaccines made therefrom, and methods of using same |
AU2019272184B2 (en) * | 2018-05-23 | 2022-01-27 | Mogam Institute For Biomedical Research | Antigen variant of varicella zoster virus and use thereof |
CA3114658A1 (en) * | 2018-09-27 | 2020-04-02 | Bravovax Co., Ltd | Immune composition, preparation method therefor and use thereof |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
CN109602901B (zh) * | 2019-01-08 | 2022-05-27 | 成都迈科康生物科技有限公司 | 一种带状疱疹病毒疫苗及其制备方法和应用 |
WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
CN112870344B (zh) * | 2019-11-29 | 2022-07-19 | 北京绿竹生物技术股份有限公司 | 一种重组水痘带状疱疹病毒疫苗 |
TW202128216A (zh) * | 2019-12-13 | 2021-08-01 | 大陸商遠大賽威信生命科學(南京)有限公司 | 免疫刺激組合物及其用途 |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
WO2022216895A1 (en) * | 2021-04-09 | 2022-10-13 | University Of Florida Research Foundation, Incorporated | Methods, kits, and approaches for viral vaccines |
CN114163503B (zh) * | 2021-12-15 | 2023-11-24 | 北京交通大学 | 两种表达水痘-带状疱疹病毒的gE蛋白的重组腺病毒及应用 |
CN115819522B (zh) * | 2022-11-19 | 2023-08-08 | 广州佰芮慷生物科技有限公司 | 一种带状疱疹病毒疫苗、表达蛋白及重组腺病毒制备与应用 |
WO2024153235A1 (zh) * | 2023-01-19 | 2024-07-25 | 厦门大学 | 一种水痘-带状疱疹病毒gE和gI的融合蛋白及应用 |
CN118240844A (zh) * | 2024-05-27 | 2024-06-25 | 北京悦康科创医药科技股份有限公司 | 带状疱疹mRNA疫苗及其制备方法和应用 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
ZA858044B (en) | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US5223424A (en) | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
US4790987A (en) | 1985-11-15 | 1988-12-13 | Research Corporation | Viral glycoprotein subunit vaccine |
US4952674A (en) * | 1986-05-02 | 1990-08-28 | Merck & Co., Inc. | Vaccine against varicella-zoster virus |
US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
US5242829A (en) | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
JP3044062B2 (ja) | 1989-03-08 | 2000-05-22 | ヘルス・リサーチ・インク | 組換えポックスウイルス宿主選択系 |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
AU645489B2 (en) | 1989-03-31 | 1994-01-20 | Washington University | Vaccines containing avirulent phoP-type microorganisms |
US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
EP0431668B1 (en) | 1989-12-04 | 1995-02-15 | Akzo Nobel N.V. | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof |
US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
US6034298A (en) | 1991-08-26 | 2000-03-07 | Prodigene, Inc. | Vaccines expressed in plants |
US5955088A (en) | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
NZ262582A (en) | 1993-01-26 | 1997-10-24 | David B Weiner | Compositions and methods for delivery of genetic material |
US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
AU700371B2 (en) | 1993-06-07 | 1999-01-07 | Genentech Inc. | Hiv envelope polypeptides |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US6156319A (en) | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
NL9401820A (nl) | 1994-11-02 | 1996-06-03 | Meyn Maschf | Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte. |
US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5650309A (en) | 1995-05-16 | 1997-07-22 | The Regents Of The University Of California | Viral vectors |
US5783383A (en) * | 1995-05-23 | 1998-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of detecting cytomegalovirus (CMV) |
US5698202A (en) | 1995-06-05 | 1997-12-16 | The Wistar Institute Of Anatomy & Biology | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
DE69835761T2 (de) | 1997-04-03 | 2007-09-13 | Electrofect As. | Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel |
CZ299473B6 (cs) | 1997-06-30 | 2008-08-06 | Rhone-Poulenc Rorer S. A. | Nukleová kyselina a elektrické pole jako sdruženýprodukt pro prenos nukleové kyseliny do bunek prícne pruhovaného svalstva |
EP2428249B1 (en) | 1998-07-13 | 2015-10-07 | Inovio Pharmaceuticals, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6589529B1 (en) | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
GB9901254D0 (en) * | 1999-01-20 | 1999-03-10 | Smithkline Beecham Biolog | Vaccines |
JP2003512305A (ja) * | 1999-09-30 | 2003-04-02 | ユニバーシティ オブ ワシントン | 免疫学的に重要な単純疱疹ウイルス抗原 |
JP2004501663A (ja) * | 2000-06-29 | 2004-01-22 | コリクサ コーポレイション | 単純疱疹ウイルス感染の診断および処置のための組成物および方法 |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
US20040175727A1 (en) | 2002-11-04 | 2004-09-09 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
WO2004076645A2 (en) * | 2003-02-27 | 2004-09-10 | University Of Massachusetts | Compositions and methods for cytomegalovirus treatment |
CA2567324C (en) | 2003-05-30 | 2012-01-03 | Advisys, Inc. | Devices and methods for biomaterial production |
WO2008051245A2 (en) * | 2005-12-02 | 2008-05-02 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
US8501194B2 (en) * | 2006-03-10 | 2013-08-06 | The Regents Of The University Of California | Vaccine for viruses that cause persistent or latent infections |
JP5872755B2 (ja) * | 2006-07-20 | 2016-03-01 | バイカル インコーポレイテッド | 抗hsv−2ワクチン接種のための組成物および方法 |
PT2066399T (pt) | 2006-10-17 | 2019-01-11 | Inovio Pharmaceuticals Inc | Dispositivos de eletroporação e métodos de usar os mesmos para eletroporação de células em mamíferos |
JP2010533737A (ja) * | 2007-07-19 | 2010-10-28 | ノババックス,インコーポレイテッド | キメラ水痘帯状疱疹ウイルス−ウイルス様粒子 |
CN101780277A (zh) * | 2009-01-15 | 2010-07-21 | 鑫品生医科技股份有限公司 | 含衍生自细胞巨大病毒的免疫原组成物及其使用方法 |
WO2010148541A1 (zh) * | 2009-06-26 | 2010-12-29 | 鑫品生医科技股份有限公司 | 含衍生自细胞巨大病毒的胜肽的免疫原组成物及使用方法 |
-
2012
- 2012-01-31 US US13/982,457 patent/US9243041B2/en active Active
- 2012-01-31 KR KR20137022593A patent/KR20140007404A/ko not_active Application Discontinuation
- 2012-01-31 AU AU2012212264A patent/AU2012212264B2/en not_active Ceased
- 2012-01-31 CN CN201280012809.5A patent/CN103827131B/zh not_active Expired - Fee Related
- 2012-01-31 JP JP2013551433A patent/JP6099573B2/ja not_active Expired - Fee Related
- 2012-01-31 BR BR112013020070A patent/BR112013020070A8/pt not_active Application Discontinuation
- 2012-01-31 CN CN201710423291.9A patent/CN107090463A/zh active Pending
- 2012-01-31 WO PCT/US2012/023398 patent/WO2012106377A2/en active Application Filing
- 2012-01-31 CA CA 2826199 patent/CA2826199A1/en not_active Abandoned
- 2012-01-31 EA EA201391109A patent/EA033467B1/ru not_active IP Right Cessation
- 2012-01-31 MX MX2013008836A patent/MX352974B/es active IP Right Grant
- 2012-01-31 EP EP12742746.6A patent/EP2670443A4/en not_active Ceased
-
2014
- 2014-11-27 HK HK14112004.3A patent/HK1198538A1/xx not_active IP Right Cessation
-
2016
- 2016-01-20 US US15/001,825 patent/US9994619B2/en active Active
- 2016-04-05 AU AU2016202122A patent/AU2016202122B2/en not_active Ceased
- 2016-11-14 JP JP2016221230A patent/JP2017035112A/ja active Pending
-
2018
- 2018-10-01 JP JP2018186496A patent/JP2019010120A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20140007404A (ko) | 2014-01-17 |
CN103827131B (zh) | 2017-06-30 |
BR112013020070A8 (pt) | 2019-09-03 |
WO2012106377A2 (en) | 2012-08-09 |
US20160130308A1 (en) | 2016-05-12 |
JP2017035112A (ja) | 2017-02-16 |
CN107090463A (zh) | 2017-08-25 |
AU2016202122B2 (en) | 2018-03-29 |
HK1198538A1 (en) | 2015-05-15 |
WO2012106377A3 (en) | 2014-03-06 |
MX2013008836A (es) | 2013-12-06 |
US9243041B2 (en) | 2016-01-26 |
AU2012212264A1 (en) | 2013-08-15 |
EA033467B1 (ru) | 2019-10-31 |
EP2670443A2 (en) | 2013-12-11 |
EA201391109A1 (ru) | 2014-03-31 |
JP6099573B2 (ja) | 2017-03-22 |
JP2019010120A (ja) | 2019-01-24 |
US20140023673A1 (en) | 2014-01-23 |
US9994619B2 (en) | 2018-06-12 |
CN103827131A (zh) | 2014-05-28 |
BR112013020070A2 (pt) | 2018-03-06 |
JP2014513522A (ja) | 2014-06-05 |
AU2012212264B2 (en) | 2016-01-28 |
EP2670443A4 (en) | 2015-10-14 |
AU2016202122A1 (en) | 2016-04-28 |
CA2826199A1 (en) | 2012-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013008836A (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
MX2018008135A (es) | Moleculas de acido nucleico de influenza y vacunas elaboradas a partir de las mismas. | |
MX343830B (es) | Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma. | |
MX2018010616A (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
PH12015500308B1 (en) | Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same | |
MX2020001385A (es) | Composiciones que comprenden construcciones geneticas y vacunas de il-12 mejoradas, agentes inmunoterapeuticos y metodos para su uso. | |
MX2014004214A (es) | Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes. | |
WO2015023461A3 (en) | Influenza nucleic acid molecules and vaccines made therefrom | |
MX355501B (es) | Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria. | |
ZA201603187B (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
MX2015013304A (es) | Vacunas de nucleoproteina de la influenza. | |
EA201990719A1 (ru) | Новые промоторы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |